好色先生

好色先生

Explore the latest content from across our publications
Join The AAN

Log In

Forgot Password?
Create New Account

Loading... please wait

2024 Annual Meeting | Industry Therapeutic Update from Alexion: Establishing Zero Relapses as the New Standard: A New Treatment Redefining NMOSD Treatment Success

Monday 04/15/24
11:45 AM - 12:45 PM MDT Add To Calendar
This program will be presented in-person only
This program is not expected to be available in the meeting's On Demand product.
Industry Therapeutic Update
Benjamin J. Osborne, MD, FAAN
General Neurology, Neuro-ophthalmology/Neuro-otology
Exploring the Devastating Impact of Relapse in NMOSD From the Patient and Physician Perspectives. 
This program is NOT accredited for continuing education by any organization. Additionally, Industry Therapeutic Updates program content and the views expressed herein are those of the presenting corporate entity and not of the AAN. These programs are not an official part of the 2024 AAN Annual Meeting education or scientific programs, nor does the AAN endorse them. The AAN cannot affirm claims pertaining to FDA off-label medication, research use of pre-FDA drugs, or other research information that might be discussed. Industry Therapeutic Updates are industry events.
No CME available

Program Evaluations

Event Timeline
11:45 AM - 12:45 PM MDT Speaker Industry Therapeutic Update from Alexion: Establishing Zero Relapses as the New Standard: A New Treatment Redefining NMOSD Treatment Success
Faculty Disclosures
Benjamin J. Osborne, MD, FAAN Dr. Osborne has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Alexion. Dr. Osborne has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Alexion. Dr. Osborne has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Amgen. Dr. Osborne has received publishing royalties from a publication relating to health care.